AB Science S.A
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyo… Read more
AB Science S.A (ABSCF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.149x
Based on the latest financial reports, AB Science S.A (ABSCF) has a cash flow conversion efficiency ratio of 0.149x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.08 Million) by net assets ($-27.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AB Science S.A - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how AB Science S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
AB Science S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AB Science S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
APEX International Financial Engineering Res & Tech Co Ltd
TWO:5210
|
0.016x |
|
Nanexa AB
ST:NANEXA
|
0.175x |
|
Lake Shore Bancorp Inc
NASDAQ:LSBK
|
0.024x |
|
DENARIUS METALS CORP.
F:T7C0
|
N/A |
|
Elementos Ltd
AU:ELT
|
-0.021x |
|
DanCann Pharma A/S
PINK:DCPXF
|
0.302x |
|
Clipper Realty Inc
NYSE:CLPR
|
-0.076x |
|
Black Mammoth Metals Corporation
PINK:LQRCF
|
-0.010x |
Annual Cash Flow Conversion Efficiency for AB Science S.A (2009–2024)
The table below shows the annual cash flow conversion efficiency of AB Science S.A from 2009 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-23.75 Million | $525.00K | -0.022x | -102.75% |
| 2023-12-31 | $-21.01 Million | $-16.87 Million | 0.803x | +63.95% |
| 2022-12-31 | $-35.67 Million | $-17.47 Million | 0.490x | -33.86% |
| 2021-12-31 | $-23.20 Million | $-17.18 Million | 0.740x | +7.14% |
| 2020-12-31 | $-19.55 Million | $-13.51 Million | 0.691x | +22.34% |
| 2019-12-31 | $-26.83 Million | $-15.16 Million | 0.565x | -68.45% |
| 2018-12-31 | $-14.96 Million | $-26.79 Million | 1.791x | +183.96% |
| 2017-12-31 | $10.73 Million | $-22.90 Million | -2.133x | -129.94% |
| 2016-12-31 | $-4.71 Million | $-33.52 Million | 7.124x | +431.03% |
| 2015-12-31 | $-17.26 Million | $-23.16 Million | 1.342x | +48.59% |
| 2014-12-31 | $-15.68 Million | $-14.16 Million | 0.903x | +102.40% |
| 2013-12-31 | $341.00K | $-12.84 Million | -37.639x | -2868.84% |
| 2012-12-31 | $4.90 Million | $-6.21 Million | -1.268x | -17.81% |
| 2011-12-31 | $7.73 Million | $-8.32 Million | -1.076x | -102.33% |
| 2010-12-31 | $14.78 Million | $-7.86 Million | -0.532x | +92.87% |
| 2009-12-31 | $1.04 Million | $-7.77 Million | -7.460x | -- |